Effect of Increasing the Dose and Duration of Sertraline Trial in the Treatment of Depressed Nursing Home Residents

Abstract

There has been limited research into defining what constitutes an adequate first-line antidepressant trial in elderly patients. The authors report the outcome of extended, high-dosage sertraline treatment in a sample of nursing home residents experiencing residual significant depressive symptoms after 10 weeks of treatment with sertraline at a final dosage of 100 mg/day. Subjects who had a Hamilton Depression Rating Scale score ≥ 12 after 10 weeks of treatment with sertraline were eligible for the 8-week open-label extension phase, which involved titrating the sertraline dosage to 200 mg/day. The cumulative response rate was 52% for the extension phase, compared with 37% for the acute phase. Examining acute phase nonresponders, 39% responded during the extension phase. Rates of discontinuation due to adverse events were comparable in the 2 phases. Our findings suggest that an extended trial or high dosages of sertraline may benefit some depressed elderly patients with persistent depression after acute treatment. (J Geriatr Psychiatry Neurol 2003; 16:109-111)

Get full access to this article

View all access options for this article.

References

1. Alexopolous GS, Katz IR, Reynolds CF III, et al. The expert consensus guideline series: pharmacotherapy of depressive disorders in older patients. Postgraduate Medicine Special Report 2001; 1-86.

2. Oslin DW, Streim J, Katz IR, et al. A heuristic comparison of sertraline with nortriptyline for the treatment of depression in the frail elderly. Am J Geriatr Psychiatry 2000; 8:141-149.

3. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatry Res 1983; 17:37-49.

4. Hamilton M. A rating scale for depression. J Neurology, Neurosurg Psychiatry 1960; 23:56-62.

5. Blessed G, Tominson BE, Roth M. The association between quantitative measures of dementia and of senile change in cerebral gray matter. Br J Psychiatry 1968; 114:797-811.

6. Guy W. ECDEU Assessment manual for psychopharmacology-revised. DHEW Pub No.(ADM) 76-338. U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976:217-222.

7. Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 1975; 12:196-198.

8. Schweizer E, Rickels K, Amsterdam JD, et al. What constitutes an adequate antidepressant trial for fluoxetine? J Clin Psychiatry 1990; 51:8-11.

9. Schweizer E, Rynn M, Mandos LA, et al. The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial. Int Clin Psychopharmacol 2001; 16:137-143.

10.

10. Preskorn SH. De-spinning in vitro data. J Pract Psychiatry Behav Health 1999; 5:283-287.

11.

11. Georgotas A, McCue RE. The benefit of extending an antidepressant trial past seven weeks in the depressed elderly. Int J Geriatr Psychiatry 1989; 4:191-195.

12.

12. Dew MA, Reynolds CF III, Houck PR, et al. Temporal profiles of the course of depression during treatment: predictors of pathways toward recovery in the elderly. Arch Gen Psychiatry 1997; 54:1016-1024.